Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
M	O
Service:	O
MEDICINE	O
Allergies:	O
No	O
Known	O
Allergies	O
/	O
Adverse	O
Drug	O
Reactions	O
Attending:	O
___.	O
Chief	O
Complaint:	O
Fatigue	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
ERCP	O
w/	O
plastic	O
CBD	O
stent	O
placement	O
on	O
___	O
History	O
of	O
Present	O
Illness:	O
Mr.	O
___	O
is	O
a	O
___	O
man	O
with	O
history	O
of	O
HTN,	O
HLD,	O
CAD	O
s/p	O
CABG	O
presenting	O
with	O
one	O
month	O
of	O
fatigue.	O
The	O
patient	O
reports	O
that	O
he	O
works	O
for	O
___,	O
and	O
left	O
1	O
month	O
ago	O
to	O
travel	O
to	O
___	O
for	O
a	O
site	O
visit.	O
He	O
reports	O
that	O
on	O
the	O
day	O
of	O
departure,	O
he	O
felt	O
nauseated,	O
had	O
abdominal	O
distention	O
and	O
gas,	O
and	O
abdominal	O
discomfort.	O
He	O
attributed	O
this	O
to	O
___	O
food	O
that	O
he	O
ate	O
prior	O
to	O
departing.	O
He	O
began	O
to	O
feel	O
fatigued.	O
He	O
noticed	O
that	O
the	O
whites	O
of	O
his	O
eyes	O
were	O
yellowed,	O
and	O
his	O
urine	O
turned	O
dark,	O
and	O
his	O
stools	O
turned	O
white.	O
He	O
denies	O
any	O
nausea,	O
vomiting,	O
or	O
diarrhea.	O
No	O
fevers	O
or	O
chills.	O
He	O
reports	O
that	O
he	O
had	O
a	O
poor	O
appetite,	O
and	O
lost	B-Weight_loss
20	O
pounds	B-Weight_loss
unintentionally.	O
Beginning	O
1	O
week	O
prior	O
to	O
admission,	O
he	O
began	O
to	O
develop	O
sharp,	O
intermittent,	O
right-sided	O
abdominal	O
pain.	O
He	O
went	O
to	O
a	O
hospital	O
in	O
___,	O
where	O
he	O
reports	O
that	O
he	O
had	O
an	O
ultrasound	O
and	O
CT	O
scan,	O
and	O
was	O
told	O
he	O
had	O
a	O
mass	O
in	O
his	O
pancreas	O
and	O
was	O
recommended	O
to	O
return	O
to	O
___	O
urgently	O
for	O
further	O
care.	O
In	O
the	O
ED,	O
initial	O
vitals:	O
96.8	O
87	O
138/67	O
18	O
99%	O
RA	O
Exam	O
notable	O
for:	O
Scleral	O
icterus,	O
jaundiced;	O
Abd:	O
Normal	O
bowel	O
sounds,	O
no	O
tenderness	O
or	O
masses	O
Labs	O
notable	O
for:	O
WBC	O
7.7,	O
Hb	O
11.2,	O
BUN/Cr	O
___,	O
AST	O
215,	O
ALT	O
157,	O
AP	O
1659,	O
lipase	O
69,	O
Tb	O
16.0,	O
Db	O
12.8,	O
Alb	O
3.3,	O
INR	O
1.9	O
Imaging	O
notable	O
for:	O
-	O
RUQUS:	O
1.	O
Mild-to-moderate	O
intrahepatic	O
biliary	O
ductal	O
dilatation	O
and	O
borderline	O
to	O
mildly	O
dilated	O
CBD	O
to	O
1.0	O
cm.	O
No	O
definite	O
obstructing	O
mass	O
or	O
stone	O
identified.	O
Cross-sectional	O
imaging	O
can	O
provide	O
further	O
assessment.	O
2.	O
Mildly	O
distended	O
gallbladder	O
with	O
biliary	O
sludge	O
without	O
gallstone	O
or	O
wall	O
thickening	O
-	O
CT	O
A/P:	O
1.	O
2.5	O
x	O
1.7	O
x	O
2.4	O
cm	O
hypoattenuating	O
mass	O
in	O
the	O
pancreatic	O
head	O
with	O
associated	O
upstream	O
intra	O
and	O
extrahepatic	O
biliary	O
ductal	O
dilatation	O
and	O
pancreatic	O
ductal	O
dilatation,	O
concerning	O
for	O
neoplasm	O
Patient	O
given:	O
1L	O
LR	O
On	O
arrival	O
to	O
the	O
floor,	O
the	O
patient	O
reports	O
that	O
he	O
feels	O
fatigued.	O
He	O
denies	O
any	O
abdominal	O
pain,	O
nausea,	O
vomiting,	O
fevers	O
at	O
present.	O
ROS:	O
Pertinent	O
positives	O
and	O
negatives	O
as	O
noted	O
in	O
the	O
HPI.	O
All	O
other	O
systems	O
were	O
reviewed	O
and	O
are	O
negative.	O
Past	O
Medical	O
History:	O
-	O
HTN	O
-	O
HLD	O
-	O
CAD	O
s/p	O
CABG	O
-	O
Osteoarthritis	O
-	O
S/p	O
right	O
TKA	O
-	O
Bilateral	O
cataracts,	B-Visual_impairment
s/p	O
left	O
cataract	B-Visual_impairment
surgery	O
Social	O
History:	O
___	O
Family	O
History:	O
Mother	O
deceased	O
at	O
___	O
from	O
pancreatic	O
cancer.	O
Physical	O
Exam:	O
ADMISSION	O
EXAM:	O
===============	O
VITALS:	O
98.3	O
108/71	O
70	O
16	O
98	O
Ra	O
GENERAL:	O
Alert	O
and	O
in	O
no	O
apparent	O
distress	O
EYES:	O
Anicteric,	O
pupils	O
equally	O
round	O
ENT:	O
Ears	O
and	O
nose	O
without	O
visible	O
erythema,	O
masses,	O
or	O
trauma.	O
Oropharynx	O
without	O
visible	O
lesion,	O
erythema	O
or	O
exudate	O
CV:	O
Heart	O
regular,	O
no	O
murmur,	O
no	O
S3,	O
no	O
S4.	O
No	O
JVD.	O
RESP:	O
Lungs	O
clear	O
to	O
auscultation	O
with	O
good	O
air	O
movement	O
bilaterally.	O
Breathing	O
is	O
non-labored	O
GI:	O
Abdomen	O
soft,	O
non-distended,	O
non-tender	O
to	O
palpation.	O
Bowel	O
sounds	O
present.	O
GU:	O
No	O
suprapubic	O
fullness	O
or	O
tenderness	O
to	O
palpation	O
MSK:	O
Neck	O
supple,	O
moves	O
all	O
extremities,	O
strength	O
grossly	O
full	O
and	O
symmetric	O
bilaterally	O
in	O
all	O
limbs	O
SKIN:	O
No	O
rashes	O
or	O
ulcerations	O
noted	O
NEURO:	O
Alert,	O
oriented,	B-Delirium
face	O
symmetric,	O
gaze	O
conjugate	O
with	O
EOMI,	O
speech	O
fluent,	O
moves	O
all	O
limbs,	O
sensation	O
to	O
light	O
touch	O
grossly	O
intact	O
throughout	O
PSYCH:	O
Very	O
pleasant,	O
appropriate	O
affect	O
.	O
.	O
Discharge	O
exam:	O
===============	O
VS:	O
___	O
1136	O
Temp:	O
98.1	O
PO	O
BP:	O
132/73	O
R	O
Lying	O
HR:	O
68	O
RR:	O
18	O
O2	O
sat:	O
98%	O
O2	O
delivery:	O
RA	O
GEN:	O
Alert,	O
NAD	O
HEENT:	O
NC/AT,	O
+mild	O
scleral	O
icterus	O
CV:	O
RR,	O
no	O
m/r/g	O
PULM:	O
CTAB	O
GI:	O
mildly	O
distended	O
abdomen,	O
soft,	O
not	O
tender	O
to	O
palpation,	O
BS	O
present	O
Neuro:	O
awake,	O
conversant	O
with	O
clear	O
speech	O
Psych:	O
calm,	O
cooperative,	O
pleasant	O
Pertinent	O
Results:	O
ADMISSION	O
LABS:	O
===============	O
___	O
03:40PM	O
BLOOD	O
WBC-7.7	O
RBC-4.16*	O
Hgb-11.2*	O
Hct-37.8*	O
MCV-91	O
MCH-26.9	O
MCHC-29.6*	O
RDW-20.5*	O
RDWSD-67.1*	O
Plt	O
___	O
___	O
03:40PM	O
BLOOD	O
Neuts-71.7*	O
Lymphs-17.6*	O
Monos-9.0	O
Eos-0.5*	O
Baso-0.4	O
Im	O
___	O
AbsNeut-5.51	O
AbsLymp-1.35	O
AbsMono-0.69	O
AbsEos-0.04	O
AbsBaso-0.03	O
___	O
04:13PM	O
BLOOD	O
___	O
PTT-35.1	O
___	O
___	O
03:40PM	O
BLOOD	O
Glucose-127*	O
UreaN-30*	O
Creat-1.6*	O
Na-141	O
K-4.8	O
Cl-105	O
HCO3-24	O
AnGap-12	O
___	O
03:40PM	O
BLOOD	O
ALT-157*	O
AST-215*	O
AlkPhos-1659*	O
TotBili-16.0*	O
DirBili-12.8*	O
IndBili-3.2	O
___	O
03:40PM	O
BLOOD	O
Lipase-69*	O
GGT-1197*	O
___	O
03:40PM	O
BLOOD	O
cTropnT-<0.01	O
___	O
03:40PM	O
BLOOD	O
Albumin-3.3*	O
Calcium-9.2	O
Phos-2.5*	O
Mg-2.6	O
.	O
.	O
NOTABLE	O
LABS	O
SINCE	O
ADMISSION:	O
=============================	O
___	O
calTIBC:	O
195*	O
Hapto:	O
148	O
Ferritin:	O
849*	O
TRF:	O
150*	O
___	O
CA	O
___:	O
10	O
(wnl)	O
___	O
INR:	O
2.2*	O
___	O
INR:	O
1.3*	O
___	O
INR:	O
1.2*	O
___	O
25	O
Vit	O
D:	O
<5*	O
.	O
.	O
IMAGING:	O
========	O
___	O
RUQUS	O
-	O
IMPRESSION:	O
1.	O
Mild-to-moderate	O
intrahepatic	O
biliary	O
ductal	O
dilatation	O
and	O
borderline	O
to	O
mildly	O
dilated	O
CBD	O
to	O
1.0	O
cm.	O
No	O
definite	O
obstructing	O
mass	O
or	O
stone	O
identified	O
Cross-sectional	O
imaging	O
can	O
provide	O
further	O
assessment.	O
2.	O
Mildly	O
distended	O
gallbladder	O
with	O
biliary	O
sludge	O
without	O
gallstone	O
or	O
wall	O
thickening.	O
.	O
___	O
CT	O
A/P	O
-	O
IMPRESSION:	O
1.	O
2.5	O
x	O
1.7	O
x	O
2.4	O
cm	O
hypoattenuating	O
mass	O
in	O
the	O
pancreatic	O
head	O
with	O
associated	O
upstream	O
intra	O
and	O
extrahepatic	O
biliary	O
ductal	O
dilatation	O
and	O
pancreatic	O
ductal	O
dilatation,	O
concerning	O
for	O
neoplasm.	O
Evaluation	O
of	O
the	O
vascular	O
involvement	O
is	O
suboptimal	O
given	O
phase	O
of	O
contrast,	O
although	O
there	O
appears	O
to	O
be	O
less	O
than	O
180	O
degree	O
involvement	O
of	O
the	O
proximal	O
SMV.	O
Dedicated	O
pancreatic	O
CTA	O
can	O
provide	O
further	O
assessment.	O
2.	O
3	O
mm	O
right	O
middle	O
lobe	O
pulmonary	O
nodule.	O
Given	O
new	O
pancreatic	O
mass,	O
dedicated	O
chest	O
CT	O
is	O
recommended	O
for	O
further	O
evaluation.	O
3.	O
Otherwise	O
no	O
acute	O
process	O
within	O
the	O
lung	O
base,	O
abdomen,	O
and	O
pelvis.	O
.	O
___	O
ERCP	O
-successful	O
ERCP	O
showing	O
a	O
tight	O
stricture	O
in	O
the	O
distal	O
third	O
of	O
the	O
bile	O
duct.	O
Status	O
post	O
stent	O
placement.	O
.	O
___	O
CT	O
chest	O
with	O
contrast	O
"FINDINGS:	O
NECK,	O
THORACIC	O
INLET,	O
AXILLAE	O
AND	O
CHEST	O
WALL:	O
The	O
thyroid	O
is	O
unremarkable.	O
No	O
enlarged	O
lymph	O
nodes	O
in	O
either	O
axilla	O
lower	O
thoracic	O
inlet.	O
No	O
abnormalities	O
on	O
the	O
chest	O
wall.	O
Mild	O
atherosclerotic	O
calcifications	O
in	O
the	O
head	O
and	O
neck	O
arteries.	O
HEART	O
AND	O
VASCULATURE:	O
The	O
heart	O
is	O
normal	O
in	O
size	O
and	O
shape.	O
No	O
pericardial	O
effusion.	O
Moderate	O
atherosclerotic	O
calcifications	O
in	O
the	O
coronary	O
arteries,	O
aorta	O
and	O
mild	O
in	O
the	O
aortic	O
valve.	O
The	O
pulmonary	O
arteries	O
and	O
aorta	O
are	O
normal	O
in	O
caliber	O
throughout.	O
Right	O
aberrant	O
subclavian	O
artery	O
as	O
a	O
normal	O
variant.	O
Penetrating	O
atherosclerotic	O
ulcer	O
in	O
the	O
proximal	O
descending	O
aorta	O
(4:77).	O
MEDIASTINUM	O
AND	O
HILA:	O
Small	O
hiatal	O
hernia.	O
The	O
esophagus	O
is	O
otherwise	O
unremarkable.	O
Small	O
mediastinal	O
lymph	O
nodes,	O
none	O
pathologically	O
enlarged	O
by	O
CT	O
size	O
criteria.	O
No	O
hilar	O
lymphadenopathy.	O
PLEURA:	O
No	O
pleural	O
effusions.	O
No	O
apical	O
scarring	O
bilaterally.	O
LUNGS:	O
The	O
airways	O
are	O
patent	O
to	O
the	O
subsegmental	O
levels.	O
Mild	O
bronchiectasis	O
in	O
both	O
lower	O
lobes.	O
No	O
bronchial	O
wall	O
thickening	O
or	O
mucous	O
plugging.	O
Diffuse	O
peripheral	O
reticular	O
opacities,	O
associated	O
to	O
mild	O
peripheral	O
calcifications,	O
and	O
mild	O
interlobular	O
septal	O
thickening.	O
No	O
honeycombing.	O
Small	O
scattered	O
solid	O
nodules,	O
as	O
follows:	O
3	O
mm	O
(4:122)	O
and	O
8	O
mm	O
(4:208)	O
nodules	O
in	O
the	O
right	O
lower	O
lobe,	O
3	O
mm	O
in	O
the	O
middle	O
lobe	O
(4:74)	O
and	O
3	O
mm	O
nodule	O
in	O
the	O
left	O
lower	O
lobe	O
(4:127).	O
CHEST	O
CAGE:	O
Severe	O
dorsal	O
spondylosis.	O
Status	O
post	O
midline	O
sternotomy.	O
No	O
acute	O
fractures.	O
No	O
suspicious	O
lytic	O
or	O
sclerotic	O
lesions.	O
UPPER	O
ABDOMEN:	O
No	O
adrenal	O
masses.	O
Please	O
refer	O
to	O
same	O
day	O
abdominal	O
CT	O
report	O
for	O
subdiaphragmatic	O
findings.	O
IMPRESSION:	O
-Small	O
solid	O
lung	O
nodules,	O
described	O
above.	O
Attention	O
on	O
follow-up	O
studies.	O
No	O
suspicious	O
lymphadenopathy	O
or	O
osseous	O
lesions.	O
-Mild	O
peripheral	O
interstitial	O
lung	O
disease.	O
-Moderate	O
atherosclerotic	O
burden	O
in	O
the	O
intrathoracic	O
vessels,	O
notably	O
with	O
a	O
penetrating	O
ulcer	O
in	O
the	O
proximal	O
descending	O
aorta.	O
Yearly	O
CTA	O
follow-up	O
is	O
recommended	O
for	O
surveillance.	O
RECOMMENDATION(S):	O
Yearly	O
CTA."	O
.	O
.	O
PATHOLOGY:	O
==========	O
-___	O
CBD	O
brushings	O
cytology:	O
POSITIVE	O
FOR	O
MALIGNANT	O
CELLS	O
-	O
consistent	O
with	O
adenocarcinoma	O
.	O
.	O
Discharge	O
labs:	O
===============	O
___	O
05:23AM	O
BLOOD	O
WBC-12.6*	O
RBC-3.90*	O
Hgb-10.7*	O
Hct-35.7*	O
MCV-92	O
MCH-27.4	O
MCHC-30.0*	O
RDW-18.4*	O
RDWSD-60.3*	O
Plt	O
___	O
___	O
05:23AM	O
BLOOD	O
Glucose-114*	O
UreaN-18	O
Creat-0.9	O
Na-141	O
K-4.7	O
Cl-105	O
HCO3-23	O
AnGap-13	O
___	O
05:23AM	O
BLOOD	O
ALT-210*	O
AST-641*	O
AlkPhos-921*	O
TotBili-5.5*	O
___	O
05:23AM	O
BLOOD	O
Albumin-2.9*	O
Calcium-8.6	O
Phos-3.2	O
Mg-1.___	O
man	O
with	O
history	O
of	O
HTN,	O
HLD,	O
CAD	O
s/p	O
CABG	O
presenting	O
with	O
one	O
month	O
of	O
fatigue	O
and	O
jaundice,	O
found	O
to	O
have	O
pancreatic	O
mass	O
with	O
obstruction.	O
.	O
#	O
Adenocarcinoma	O
of	O
bile	O
duct	O
&	O
pancreas	O
#	O
Malignant	O
biliary	O
stricture	O
with	O
obstruction	O
Patient	O
presented	O
with	O
1	O
month	O
of	O
malaise	O
and	O
jaundice,	O
found	O
to	O
have	O
transaminitis	O
and	O
hyperbilirubinemia	O
with	O
imaging	O
evidence	O
of	O
pancreatic	O
head	O
mass	O
and	O
biliary	O
ductal	O
dilatation.	O
ERCP	O
showed	O
tight	O
stricture	O
in	O
distal	O
CBD	O
and	O
he	O
underwent	O
stenting	O
without	O
sphincterotomy	O
because	O
INR	O
was	O
2.2	O
at	O
that	O
time.	O
Following	O
stenting	O
his	O
TBili	O
improved	O
significantly	O
(16	O
-->	O
5.5)	O
and	O
his	O
Alk	O
phos	O
also	O
improved	O
markedly	O
(1659	O
-->	O
921)	O
and	O
he	O
felt	O
much	O
better	O
with	O
improved	O
appetite.	O
On	O
day	O
of	O
discharge	O
he	O
was	O
tolerating	O
a	O
regular	O
diet	O
with	O
no	O
GI	O
symptoms.	O
Cytology	O
(CBD	O
brushings)	O
ultimately	O
showed	O
adenocarcinoma.	O
Oncology	O
was	O
consulted	O
and	O
recommended	O
follow-up	O
in	O
___	O
multi-disciplinary	O
pancreatic	O
tumor	O
clinic;	O
patient's	O
appointment	O
is	O
scheduled	O
for	O
___,	O
at	O
1:00	O
___.	O
.	O
#	O
Acute	O
kidney	O
injury:	O
Last	O
known	O
Cr	O
1.0	O
(___),	O
1.6	O
on	O
admission.	O
Suspect	O
pre-renal	O
azotemia	O
in	O
setting	O
of	O
poor	O
oral	O
intake.	O
Improved	O
after	O
IVFs	O
and	O
with	O
holding	O
lisinopril.	O
Cr	O
0.9	O
prior	O
to	O
discharge.	O
Can	O
resume	O
lisinopril	O
at	O
rehab/home	O
if	O
persistently	O
hypertensive	O
(SBP	O
>	O
140	O
or	O
DBP	O
>	O
90)	O
.	O
#	O
Anemia:	O
Prior	O
Hgb	O
13.9	O
(___),	O
11.2	O
on	O
admission	O
without	O
evidence	O
of	O
active	O
bleeding,	O
No	O
evidence	O
of	O
hemolysis	O
on	O
labs.	O
H/H	O
stable	O
since	O
___.	O
.	O
#	O
Coagulopathy:	O
INR	O
2.2	O
on	O
admission.	O
Suspect	O
nutritional	B-Malnutrition
due	O
to	O
poor	B-Malnutrition
oral	O
intake.	O
INR	O
normalized	O
after	O
IV	O
vitamin	O
K.	O
Started	O
on	O
multivitamin.	O
.	O
#	O
Vit	O
D	O
deficiency:	O
suspected	O
based	O
on	O
Vit	O
K	O
deficiency;	O
added-on	O
Vit	O
D	O
level	O
and	O
confirmed;	O
severe	O
deficiency	O
(serum	O
25VitD	O
<	O
5).	O
Initiated	O
repletion	O
with	O
50,000	O
units	O
to	O
be	O
given	O
daily	O
x5	O
days,	O
then	O
weekly	O
for	O
next	O
7	O
weeks.	O
[]	O
please	O
repeat	O
Vit	O
D	O
level	O
in	O
4	O
weeks	O
to	O
ensure	O
improving	O
.	O
#	O
Constipation:	B-Constipation
this	O
was	O
the	O
issue	O
that	O
bothered	O
him	O
the	O
most;	O
no	O
BM	O
for	O
~4	O
days,	O
was	O
given	O
bowel	O
regimen	O
and	O
after	O
resuming	O
PO	O
and	O
some	O
activity,	O
had	O
large	O
BM	O
on	O
___	O
and	O
patient	O
felt	O
much	O
better.	O
Continued	O
bowel	O
regimen	O
upon	O
discharge.	O
.	O
#	O
HTN	O
-	O
continued	O
home	O
metoprolol	O
-	O
held	O
home	O
lisinopril	O
in	O
setting	O
___	O
as	O
above,	O
can	O
be	O
resumed	O
at	O
rehab	O
if	O
he	O
is	O
persistently	O
hypertensive	O
.	O
#	O
HLD	O
-	O
Holding	O
home	O
Vytorin	O
(non-formulary);	O
resumed	O
upon	O
discharge	O
.	O
#	O
CAD	O
s/p	O
CABG:	O
-	O
held	O
home	O
ASA	O
(due	O
to	O
initial	O
need	O
for	O
procedure),	O
statin;	O
resumed	O
on	O
discharge	O
.	O
#	O
Penetrating	O
atherosclerotic	O
ulcer	O
in	O
the	O
proximal	O
descending	O
aorta	O
**NEW	O
INCIDENTAL	O
FINDING**	O
[]	O
yearly	O
CTA	O
for	O
follow-up	O
.	O
.	O
.	O
TRANSITIONAL	O
ISSUES:	O
====================	O
*New	O
dx	O
of	O
adenocarcinoma	O
of	O
common	O
bile	O
duct/pancreas;	O
has	O
f/u	O
scheduled	O
in	O
___	O
Pancreatic	O
Tumor	O
clinic.	O
*New	O
dx	O
of	O
Vit	O
D	O
deficiency,	O
started	O
on	O
repletion	O
[]	O
please	O
repeat	O
Vit	O
D	O
level	O
in	O
4	O
weeks	O
to	O
ensure	O
improving	O
*New	O
incidental	O
finding	O
of	O
penetrating	O
atherosclerotic	O
ulcer	O
in	O
the	O
proximal	O
descending	O
aorta	O
[]	O
yearly	O
CTA	O
for	O
follow-up	O
.	O
.	O
.	O
.	O
.	O
Time	O
in	O
care:	O
>	O
45	O
minutes	O
in	O
discharge-related	O
activities	O
today.	O
.	O
.	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
magnesium	O
oxide	O
250	O
mg	O
oral	O
BID	O
2.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
3.	O
Vytorin	O
___	O
(ezetimibe-simvastatin)	O
___	O
mg	O
oral	O
QHS	O
4.	O
Lisinopril	O
10	O
mg	O
PO	O
DAILY	O
5.	O
Aspirin	O
325	O
mg	O
PO	O
DAILY	O
Discharge	O
Medications:	O
1.	O
Bisacodyl	O
___AILY:PRN	O
Constipation	B-Constipation
-	O
Second	O
Line	O
Reason	O
for	O
PRN	O
duplicate	O
override:	O
Alternating	O
agents	O
for	O
similar	O
severity	O
2.	O
Docusate	O
Sodium	O
100	O
mg	O
PO	O
BID	O
3.	O
Multivitamins	O
1	O
TAB	O
PO	O
DAILY	O
4.	O
Polyethylene	O
Glycol	O
17	O
g	O
PO	O
DAILY:PRN	O
Constipation	B-Constipation
-	O
Second	O
Line	O
5.	O
Senna	O
8.6	O
mg	O
PO	O
BID:PRN	O
Constipation	B-Constipation
-	O
First	O
Line	O
6.	O
Vitamin	O
D	O
___	O
UNIT	O
PO	O
DAILY	O
Duration:	O
3	O
Doses	O
After	O
completes	O
next	O
3	O
daily	O
doses,	O
should	O
convert	O
to	O
once	O
weekly	O
dosing	O
for	O
next	O
7	O
weeks.	O
7.	O
Aspirin	O
325	O
mg	O
PO	O
DAILY	O
8.	O
magnesium	O
oxide	O
250	O
mg	O
oral	O
BID	O
9.	O
Metoprolol	O
Tartrate	O
25	O
mg	O
PO	O
BID	O
10.	O
Vytorin	O
___	O
(ezetimibe-simvastatin)	O
___	O
mg	O
oral	O
QHS	O
11.	O
HELD-	O
Lisinopril	O
10	O
mg	O
PO	O
DAILY	O
This	O
medication	O
was	O
held.	O
Do	O
not	O
restart	O
Lisinopril	O
until	O
your	O
blood	O
pressure	O
is	O
persistently	O
elevated	O
(SBP	O
>	O
140	O
or	O
DBP	O
>	O
90)	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
___	O
Diagnosis:	O
Pancreatic	O
Adenocarcinoma	O
Bile	O
Duct	O
Obstruction	O
Vitamin	O
K	O
deficiency	O
Vitamin	O
D	O
deficiency	O
Moderate	O
malnutrition	B-Malnutrition
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Alert	O
and	O
interactive.	O
Activity	O
Status:	O
Ambulatory	B-Mobile_with_assistance
-	B-Mobile_with_assistance
requires	B-Mobile_with_assistance
assistance	B-Mobile_with_assistance
or	O
aid	B-Mobile_with_aid
(walker	O
or	O
cane).	O
Discharge	O
Instructions:	O
Mr.	O
___,	O
You	O
presented	O
to	O
the	O
hospital	O
with	O
evidence	O
of	O
biliary	O
obstruction	O
and	O
a	O
pancreatic	O
mass.	O
You	O
underwent	O
a	O
procedure	O
called	O
an	O
ERCP,	O
during	O
which	O
a	O
stent	O
was	O
placed	O
in	O
your	O
bile	O
ducts	O
and	O
samples	O
were	O
taken.	O
Unfortunately,	O
these	O
samples	O
returned	O
consistent	O
with	O
a	O
pancreatic	O
cancer.	O
But	O
fortunately,	O
the	O
stent	O
that	O
was	O
placed	O
helped	O
you	O
feel	O
better,	O
your	O
jaundice	O
improved,	O
and	O
your	O
appetite	O
improved.	O
You	O
are	O
scheduled	O
to	O
follow-up	O
in	O
the	O
___	O
Pancre___	O
Specialty	O
Clinic	O
on	O
___,	O
___,	O
at	O
1PM	O
(see	O
below	O
for	O
details).	O
You	O
were	O
also	O
found	O
to	O
have	O
vitamin	O
D	O
deficiency,	O
likely	O
a	O
direct	O
result	O
of	O
the	O
biliary	O
obstruction	O
you	O
had,	O
which	O
is	O
now	O
improved.	O
We	O
are	O
repleting	O
your	O
deficiency	O
with	O
high-dose	O
vitamin	O
D,	O
and	O
this	O
will	O
need	O
to	O
be	O
rechecked	O
in	O
___	O
months	O
by	O
your	O
primary	O
care	O
physician	O
to	O
ensure	O
that	O
your	O
Vitamin	O
D	O
level	O
is	O
improving.	O
It	O
was	O
a	O
pleasure	O
caring	O
for	O
you	O
and	O
we	O
wish	O
you	O
all	O
the	O
best.	O
Sincerely,	O
Dr.	O
___	O
the	O
___	O
Medicine	O
Team	O
Followup	O
Instructions:	O
___	O

